KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Common Equity: 2019-2024

Historic Common Equity for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $1.1 billion.

  • AbCellera Biologics' Common Equity fell 10.58% to $964.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.0 million, marking a year-over-year decrease of 10.58%. This contributed to the annual value of $1.1 billion for FY2024, which is 8.35% down from last year.
  • Per AbCellera Biologics' latest filing, its Common Equity stood at $1.1 billion for FY2024, which was down 8.35% from $1.2 billion recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Common Equity registered a high of $1.2 billion during FY2022, and its lowest value of $830.5 million during FY2020.
  • Its 3-year average for Common Equity is $1.1 billion, with a median of $1.2 billion in 2023.
  • As far as peak fluctuations go, AbCellera Biologics' Common Equity spiked by 8,000.94% in 2020, and later declined by 8.35% in 2024.
  • AbCellera Biologics' Common Equity (Yearly) stood at $830.5 million in 2020, then rose by 23.51% to $1.0 billion in 2021, then rose by 20.23% to $1.2 billion in 2022, then declined by 6.56% to $1.2 billion in 2023, then decreased by 8.35% to $1.1 billion in 2024.